Last updated on May 2017

A Clinical Study in Subjects With Huntington's Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod


Brief description of study

The primary objective of this study is to assess the efficacy of laquinimod 0.5, 1.0, and 1.5 mg qd in patients with HD after 12 months of treatment using the UHDRS-TMS.

Clinical Study Identifier: NCT02215616

Contact Investigators or Research Sites near you

Start Over

Teva U.S. Medical Information

Teva Investigational Site 34178
Cardiff, United Kingdom
  Connect »